Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter.
How Weight-Loss Drugs Can Upend a Marriage
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of conversations with her husband, Javier. They were in
Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets. On an adjusted basis, the U.S.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating."
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates. Eli Lilly reported net income of $4.41 billion, or $4.
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Lilly says Mounjaro and Zepbound contributed to big revenue boost
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in ...
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...
Lilly forecasts 2025 profit above estimates on weight-loss drug strength
The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...